Double-blind placebo-controlled trial of erythromycin in the treatment of clinical campylobacter infection

Mandal, B K; Ellis, Michael; Dunbar, E M; Whale, K

doi:10.1093/jac/13.6.619

Cited by 47 publications

(24 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In most immunocompetent individuals, campylobacteriosis is a self-limiting disease, and treatment with antimicrobials reduces the period of fecal shedding but does not have a large impact on the duration of disease symptoms (4,105,180). However, when given early, some clinical benefit has been observed (126,147).…”

Section: Pathology and Pathophysiology Of Campylobacter Infectionmentioning

confidence: 99%

Host-Pathogen Interactions inCampylobacterInfections: the Host Perspective

et al. 2008

View full text Add to dashboard Cite

SUMMARY Campylobacter is a major cause of acute bacterial diarrhea in humans worldwide. This study was aimed at summarizing the current understanding of host mechanisms involved in the defense against Campylobacter by evaluating data available from three sources: (i) epidemiological observations, (ii) observations of patients, and (iii) experimental observations including observations of animal models and human volunteer studies. Analysis of available data clearly indicates that an effective immune system is crucial for the host defense against Campylobacter infection. Innate, cell-mediated, and humoral immune responses are induced during Campylobacter infection, but the relative importance of these mechanisms in conferring protective immunity against reinfection is unclear. Frequent exposure to Campylobacter does lead to the induction of short-term protection against disease but most probably not against colonization. Recent progress in the development of more suitable animal models for studying Campylobacter infection has opened up possibilities to study the importance of innate and adaptive immunity during infection and in protection against reinfection. In addition, advances in genomics and proteomics technologies will enable more detailed molecular studies. Such studies combined with better integration of host and pathogen research driven by epidemiological findings may truly advance our understanding of Campylobacter infection in humans.

show abstract

Section: Pathology and Pathophysiology Of Campylobacter Infectionmentioning

confidence: 99%

Host-Pathogen Interactions inCampylobacterInfections: the Host Perspective

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Although the disease is generally self-limiting, early antibiotic treatment may alleviate the discomfort and pain and reduce the excretion period (Mandal & Ellis, 1983). Unfortunately, the isolation of C. jejuni from faeces requires a 48 h incubation time, in the presence of selective antibiotics, under demanding microaerophilic conditions.…”

Section: Introductionmentioning

confidence: 99%

Monoclonal antibodies directed against the flagella ofCampylobacter jejuni: cross-reacting and serotypic specificity and potential use in diagnosis

Newell

1986

J. Hyg.

View full text Add to dashboard Cite

SUMMARYNine monoclonal antibodies directed against the flagella ofCampylobacter jejunistrain 81116 have been investigated for serotypic and cross-reacting activity using a panel of 17 Penner serotype strains ofC. jejuni.Four monoclonal antibodies were exclusively specific for serotype-6 strains, which was the serotype ofC. jejunistrain 81116. Two monoclonal antibodies cross-reacted with all the flagellated strains ofC jejunitested. One of these cross-reacting monoclonal antibodies, CF5, was found to react with all otherCampylobacterspecies exceptC. sputorum bulbulusbut it did not react with other bacterial entcropathogens. An antigencapture ELISA technique was established, using this monoclonal antibody, which could detect flagellar antigen in human faecal material. These anti-flagella monoclonal antibodies therefore may be valuable in the diagnosis and serotyping ofC. jejuniin clinical material.

show abstract

“…In a number of clinical trials performed in adults and children, erythromycin has not been shown to significantly alter the clinical course of Campylobacter infection (1,12,13,15,16,20). Results of one study, however, found that when Peruvian children with bloody diarrhea due to Campylobacter isolates were treated early in the course of illness with erythromycin, they improved earlier than children given placebo (21).…”

mentioning

confidence: 99%